Yale researchers see decline in hospitalizations for serious heart infection

September 16, 2013

Hospitalizations for endocarditis, a deadly heart infection that disproportionately affects older heart patients, have declined in recent years despite recommendations for limited use of antibiotics to prevent the illness. These findings were recently published by Yale School of Medicine researchers in the Journal of the American College of Cardiology.

Endocarditis is the most serious infection of the cardiovascular system, and the risk increases with surgical procedures. Past studies showed a marked increase in endocarditis during the 1990s. As a preventative measure, many clinicians routinely prescribed antibiotics before dental procedures, and gastrointestinal and other types of surgeries.

While endocarditis risk factors, such as , have declined recently, the risk has increased for those with and prosthetic valves. In addition, the American Heart Association narrowed the for endocarditis to only a subgroup of patients undergoing dental procedures.

In light of these changes, the Yale research team, led by first author Behnood Bikdeli, M.D., postdoctoral associate in at the Yale Center for Outcomes Research and Evaluation, assessed the annual rates of endocarditis hospitalization and the related outcomes among 262,658 Medicare patients aged 65 and older from 1999 through 2010.

The study showed an increase in endocarditis hospitalizations from 1999 to 2005. However from 2006 to 2010, the team saw no increase, but instead noticed a decline. "We were surprised to see reduced rates of endocarditis hospitalizations during this time period," said Bikdeli who is also an internal medicine resident at Yale. "This downward trend was consistent in all major study subgroups, but certain subgroups, including black participants, had higher hospitalization rates and worse outcomes in the study period."

Bikdeli said this racial disparity in outcomes, as well as reasons for the overall decline in hospitalizations, should be investigated further. He added, "We would ideally like to see comparative effectiveness studies, such as randomized trials, to test antibiotics' efficacy, but due to the expense and the minimal potential effects of antibiotics, such a study would be unlikely in the near future. Therefore, surveillance investigations such as ours are particularly important to monitor the disease and outcomes."

"Clinicians should consider the risks and benefits of antibiotic-use on a case-by-case basis and should share the information with their patients for appropriate decision making," Bikdeli concluded.

Explore further: Surgery improves endocarditis-induced heart failure survival rates

More information: Journal of the American College of Cardiology DOI: 10.1016/j.jacc.2013.07.071

Related Stories

All water pills not equally effective against heart failure

April 1, 2013

Loop diuretics, more commonly known as water pills, are the most widely prescribed heart failure medications, but few studies had extensively compared their effectiveness until Yale School of Medicine researchers examined ...

Bacterial toxins cause deadly heart disease

August 20, 2013

University of Iowa researchers have discovered what causes the lethal effects of staphylococcal infective endocarditis - a serious bacterial infection of heart valves that kills approximately 20,000 Americans each year.

High burden of endocarditis in older adults

September 15, 2013

(HealthDay)—The 2007 American Heart Association guidelines recommending a restriction of antibiotic prophylaxis have not increased the rates of hospitalization or adjusted mortality for endocarditis among Medicare beneficiaries, ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.